Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Status:
Not yet recruiting
Trial end date:
2028-05-15
Target enrollment:
Participant gender:
Summary
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with
Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial
(AG10-301)